Literature DB >> 359950

Properties of human malignant glioma cells in vitro.

J Pontén, B Westermark.   

Abstract

The properties of human glia and glioma cells in culture are reviewed. Glia-like cells from non-neoplastic brain show all accepted hallmarks of normalcy: limited life span, low terminal cell density, strong density dependent inhibition of proliferation, diploidy and contact inhibition of membrane mobility. Twenty five glioma lines have been studied. They all showed infinite life span, increased terminal cell density, relaxed density dependent inhibition of proliferation, aneuploidy and deficient contact inhibition of membrane mobility. So far all attempts to explain these departures from normal on the basis of a single metabolic defect have failed. Instead, all tested lines have shown an individual mosaic of structural and/or metabolic abnormalities characteristic for each line. This was particulary well demonstrated in studies of the glycosaminoglykans. The possibility is discussed that a malignant phenotype can a rise and exist in an almost infinite number of ways. The essential feature may be the acquisition of infinite growth potential which will set the stage for multiplication of genetic variants with an ever increasing fitness for proliferation and spread.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 359950

Source DB:  PubMed          Journal:  Med Biol        ISSN: 0302-2137


  59 in total

1.  Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration.

Authors:  X Fang; M A Burg; D Barritt; K Dahlin-Huppe; A Nishiyama; W B Stallcup
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

2.  Induction and characterization of human glioma clones with different radiosensitivities.

Authors:  J Wang; L Hu; N Gupta; T Shamseldin; T Ozawa; J Klem; M Cardell; D F Deen
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

3.  The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2.

Authors:  D S Barritt; M T Pearn; A H Zisch; S S Lee; R T Javier; E B Pasquale; W B Stallcup
Journal:  J Cell Biochem       Date:  2000-08-02       Impact factor: 4.429

4.  The 56 kd platelet-derived growth factor (PDGF)-related protein is phosphorylated and the most stable form in human glioma cells.

Authors:  T Nakamura; I Takeshita; T Inamura; M Fukui
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

5.  Establishment and characterization of five cell lines derived from human malignant gliomas.

Authors:  J T Rutka; J R Giblin; D Y Dougherty; H C Liu; J R McCulloch; C W Bell; R S Stern; C B Wilson; M L Rosenblum
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

6.  DNA content and marker expression in human glioma explants.

Authors:  R D Davenport; P E McKeever
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

7.  Products of cultured neuroglial cells: II. The production of fibronectin by C6 glioma cells.

Authors:  J R Baldwin; P E McKeever; T R Booker
Journal:  Neurochem Res       Date:  1985-05       Impact factor: 3.996

8.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

Authors:  C K Goldman; J Kim; W L Wong; V King; T Brock; G Y Gillespie
Journal:  Mol Biol Cell       Date:  1993-01       Impact factor: 4.138

9.  Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival.

Authors:  Rainer Glass; Michael Synowitz; Golo Kronenberg; Joo-Hee Walzlein; Darko S Markovic; Li-Ping Wang; Daniela Gast; Jürgen Kiwit; Gerd Kempermann; Helmut Kettenmann
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

10.  Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas.

Authors:  P E McKeever; J Varani; S M Papadopoulos; M Wang; J P McCoy
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.